|
US5846547A
(en)
*
|
1996-01-22 |
1998-12-08 |
Regents Of The University Of Minnesota |
Streptococcal C5a peptidase vaccine
|
|
US6355255B1
(en)
*
|
1998-12-07 |
2002-03-12 |
Regents Of The University Of Minnesota |
Streptococcal C5a peptidase vaccine
|
|
US6676943B1
(en)
|
1997-04-24 |
2004-01-13 |
Regents Of The University Of Minnesota |
Human complement C3-degrading protein from Streptococcus pneumoniae
|
|
US6444787B1
(en)
*
|
1997-12-31 |
2002-09-03 |
Research Development Institute, Inc. |
Method of isolating a peptide which immunologically mimics microbial carbohydrates including group B streptococcal carbohydrates and the use thereof in a vaccine
|
|
BR9914066A
(pt)
*
|
1998-09-24 |
2002-04-23 |
Univ Minnesota |
Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae
|
|
US7256265B2
(en)
*
|
1999-12-03 |
2007-08-14 |
Regents Of The University Of Minnesota |
Streptococcal C5a peptidase vaccine
|
|
ES2330083T3
(es)
*
|
2000-10-27 |
2009-12-04 |
Novartis Vaccines And Diagnostics S.R.L. |
Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
|
|
AU2004226909B2
(en)
*
|
2000-10-27 |
2008-02-07 |
J. Craig Venter Institute, Inc. |
Nucleic acids and proteins from streptococcus groups A & B
|
|
GB2370770B
(en)
*
|
2001-01-03 |
2005-06-01 |
Simon Connolly |
Uses of Streptococcus Vaccines
|
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
|
AU2003260102A1
(en)
*
|
2002-08-26 |
2004-03-11 |
Chiron Corporation |
Conserved and specific streptococcal genomes
|
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
|
US7301554B2
(en)
*
|
2002-09-20 |
2007-11-27 |
Ricoh Company, Ltd. |
Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
|
|
ES2505695T3
(es)
|
2003-07-31 |
2014-10-10 |
Novartis Vaccines And Diagnostics, Inc. |
Composiciones inmunógenas para Streptococcus pyogenes
|
|
US8945589B2
(en)
*
|
2003-09-15 |
2015-02-03 |
Novartis Vaccines And Diagnostics, Srl |
Immunogenic compositions for Streptococcus agalactiae
|
|
CA2575548A1
(en)
|
2004-07-29 |
2006-07-27 |
John L. Telford |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
|
EP1807446A2
(en)
*
|
2004-10-08 |
2007-07-18 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic and therapeutic compositions for streptococcus pyogenes
|
|
TW200806315A
(en)
*
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
PT2054431E
(pt)
*
|
2006-06-09 |
2011-11-03 |
Novartis Ag |
Confórmeros de adesinas bacterianas
|
|
US7364291B2
(en)
*
|
2006-06-29 |
2008-04-29 |
Johnson & Johnson Vision Care, Inc. |
Contact lenses with light blocking rings
|
|
WO2008108830A2
(en)
*
|
2006-10-30 |
2008-09-12 |
Novartis Ag |
Immunogenic and therapeutic compositions for streptococcus pyogenes
|
|
US20080311129A1
(en)
*
|
2006-11-02 |
2008-12-18 |
Camas Incorporated |
Adherence inhibitor directed to and method of making and using
|
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
|
HU227970B1
(en)
|
2007-07-10 |
2012-07-30 |
Egis Gyogyszergyar Nyrt |
Pharmaceutical compositions containing silicones of high volatility
|
|
JP5653215B2
(ja)
|
2007-09-12 |
2015-01-14 |
ノバルティス アーゲー |
Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
|
|
EP2537857B1
(en)
*
|
2007-12-21 |
2017-01-18 |
GlaxoSmithKline Biologicals SA |
Mutant forms of streptolysin O
|
|
EP2356135B1
(en)
|
2008-11-05 |
2017-10-25 |
Wyeth LLC |
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
|
|
AU2011262346B2
(en)
|
2010-06-04 |
2014-12-11 |
Wyeth Llc |
Streptococcus pneumoniae vaccine formulations
|
|
DK2608805T4
(da)
|
2010-08-23 |
2025-06-30 |
Wyeth Llc |
STABILE FORMULERINGER AF NEISSERIA MENINGITIDIS rLP2086 ANTIGENER
|
|
RU2546873C2
(ru)
|
2010-09-10 |
2015-04-10 |
УАЙТ ЭлЭлСи |
Нелипидизированные варианты антигенов neisseria meningitidis orf2086
|
|
ITMI20111182A1
(it)
|
2011-06-28 |
2012-12-29 |
Canio Buonavoglia |
Vaccino per coronavirus canino
|
|
US9078842B2
(en)
|
2011-10-26 |
2015-07-14 |
Wisconsin Alumni Research Foundation |
Peptide for reducing the phosphate requirement and excretion from farm animals
|
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
|
PE20190458A1
(es)
|
2012-03-09 |
2019-04-01 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de las mismas
|
|
WO2014136064A2
(en)
|
2013-03-08 |
2014-09-12 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
|
CA2923129C
(en)
|
2013-09-08 |
2020-06-09 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
|
EP2886140A1
(en)
*
|
2013-12-17 |
2015-06-24 |
University of Limerick |
An apparatus for the extracorporeal treatment of blood
|
|
US9107906B1
(en)
|
2014-10-28 |
2015-08-18 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
|
MX391027B
(es)
|
2015-02-19 |
2025-03-21 |
Pfizer |
Composiciones de neisseria meningitidis y metodos de la misma.
|
|
US10544197B2
(en)
|
2016-08-12 |
2020-01-28 |
Wisconsin Alumni Research Foundation |
FGF-23 epitope peptide for improving resistance to breakage and eggshell strength
|
|
PE20191107A1
(es)
|
2017-01-31 |
2019-08-26 |
Pfizer |
Composiciones de neisseria meningitidis y metodos respectivos
|
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
|
CN115605222A
(zh)
|
2019-09-27 |
2023-01-13 |
辉瑞公司（Us） |
脑膜炎奈瑟氏菌组合物及其方法
|
|
EP4237428A2
(en)
|
2020-10-27 |
2023-09-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
US12357681B2
(en)
|
2020-12-23 |
2025-07-15 |
Pfizer Inc. |
E. coli FimH mutants and uses thereof
|
|
CA3221074A1
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
JP2024521847A
(ja)
|
2021-05-28 |
2024-06-04 |
ファイザー・インク |
コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
JP2025508749A
(ja)
|
2022-01-13 |
2025-04-10 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
|
PE20251701A1
(es)
|
2022-11-22 |
2025-07-02 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
|
|
EP4661911A1
(en)
|
2023-02-10 |
2025-12-17 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2024201324A2
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
AU2024255922A1
(en)
|
2023-04-14 |
2025-10-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2024224266A1
(en)
|
2023-04-24 |
2024-10-31 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2025057078A1
(en)
|
2023-09-14 |
2025-03-20 |
Pfizer Inc. |
Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
|
|
WO2025133971A1
(en)
|
2023-12-23 |
2025-06-26 |
Pfizer Inc. |
Improved methods for producing bacterial capsular saccharide glycoconjugates
|
|
WO2025186705A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2025191415A1
(en)
|
2024-03-11 |
2025-09-18 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
|
|
WO2025219904A1
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
|
|
WO2025219908A2
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Media and fermentation methods for polysaccharide production in bacterial cell culture
|